singly or collectively, express a cellular targeting protein and retroviral gag and pol genes in amounts sufficient to package said RVP; and

(b) recovering said packaging cell line:[.]

with the proviso that the non-primate mammalian cell line is not BHK.

- 3. (twice amended) The method of Claim 1, wherein said cell line [expresses galactose α (1,3) galactosyl epitopes and is not treated to reduce such expression] is human serum-resistant.
- 20. (amended) Retroviral vector particles produced by the methods of any one of Claims 11. [12,] 16, 44 or [41] 45.
- 46. (amended) A method for preparing a stable, retroviral packaging cell line for generation of human serum-resistant retroviral particles (RVP) which comprises
- (a) introducing one or more packaging vectors into a <u>human serum-resistant</u> non-primate mammalian cell line, [wherein said cell line expresses galactose α (1,3) galactosyl epitopes and is not treated to reduce such expression, and] wherein said vectors, either singly or collectively, express a cellular targeting protein and retroviral *gag* and *pol* genes in amounts sufficient to package said RVP; and

(b) recovering said packaging cell line.

(amended) The method of Claim 46, wherein said cell line exhibits [substantially] no specific hybridization to a Moloney-MLV retrovirus [gag, pol,] gag-pol or env probe[under stringent washing conditions].

In Claim 50, please delete "produed" and insert therefor --produced--.
In Claim 51, at line 5, please delete "or" and insert therefor --of--.

- 53. (amended) The method of Claim 51, wherein said cells exhibit [substantially] no specific hybridization to a Moloney-MLV retrovirus [gag, pol,] gag-pol or env probe[under stringent washing conditions].
- 58. (amended) The method of Claim 56 wherein said cell line exhibits [substantially] no specific hybridization to a Moloney-MLV retrovirus [gag, pol,] gag-pol or env probe[under stringent washing conditions].